Discovery of Preclinical candidates of new PKM2 activator that cure inflammation and fibrosis at the same time through cell metabolism modulation

Lmito Therapeutics

IMMUNOLOGY	Candidate
Product Type	Chemical-Small Molecule
Indication	1st Indication : Idiopathic pulmonary fibrosis 2nd Indication : Rheumatoid arthritis
Target	Pyruvate kinase M2 (PKM2)
MoA(Mechanism of Action)	PKM2 activator(PKM2 dimer \rightarrow PKM2 tetramer \rightarrow Increase glycolytic activity)
Competitiveness	Using artificial intelligence (AI) and molecular modeling technology together, several numbers of Hits were discovered swiftly in a short amount of time less than two months, and these technologies are also applied to the optimization process for accelerating development speed, thereby to develop new PKM2 activator as a First-in-class drug.
Development Stage	Candidate
Route of Administration	n Oral

